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EX VIVO AND IN VIVO METHODS AND 
RELATED COMPOSITIONS FOR 
GENERATING HEMATOPOIETIC STEM 
CELL POPULATIONS 
CROSS-REFERENCES 
This application is a non-provisional application that 
claims priority under 35 U.S.C. §119 to US. Provisional 
Application No. 60/722,755 entitled MANIPULATION OF 
ADULT STEM CELL POPULATION SIZES BY LATEXIN 
and ?led on Sep. 30, 2005, the entire content of Which is 
hereby incorporated by reference. 
STATEMENT OF GOVERNMENT INTEREST 
This invention has been made With Government support 
under grant number ROI AG024950, aWarded by the National 
Institute on Aging. The government has certain rights in the 
invention. 
TECHNICAL FIELD 
The present invention relates to methods for regenerating 
adult hematopoietic stem cells (HSCs) and related composi 
tions by reducing/inhibiting latexin expression and/ or latexin 
activity. 
INCORPORATION-BY-REFERENCE & TEXTS 
The material on the accompanying CD-R is hereby incor 
porated by reference into this application. The accompanying 
compact disc contains one ?le, 1028750-000249 
HSCS.ST25.txt, Which Was created on Oct. 2, 2006. The ?le 
named 1028750-000249 HSCS.ST25.txt is 5 KB. The ?le can 
be accessed using Microsoft Word on a computer that uses 
WindoWs OS. 
BACKGROUND OF THE INVENTION 
Hematopoiesis is a complex process for producing mul 
tiple and distinct lineages of blood-borne cells throughout the 
life span of an organism. Hematopoietic stem cells (“HSCs”) 
represent a subset of undifferentiated cells that resides pre 
dominantly in the bone marroW of adult mammals. HSCs, as 
a population, are capable of self-reneWal by maintaining a 
suf?cient number of HSCs Within an organism’s bone mar 
roW as a reservoir of uncommitted cells that can be further 
differentiated into various types of neW blood cells. Such 
neWly generated blood cells emerge from the bone marroW 
and enter the circulatory system in order to continuously 
replace mature/ aging circulating blood cell types. The ability 
of HSCs, as a population, to differentiate and to give rise to 
cells of multi-lineages is critical for the preservation of an 
organism. 
In order for the maintenance of steady-state hematopoiesis, 
a balance must be achieved betWeen the rate of self-genera 
tion (i.e., for maintaining a steady supply of HSCs) and the 
rate of differentiation (i.e., for replenishing senescent cells). 
Hematopoiesis occurs as a developmental continuum in that a 
given population of HSCs is representative of a heteroge 
neous mixture of cells, mainly composed of long-term HSCs 
(“LT-HSCs”) and short-term HSCs (“ST-HSCs”). LT-HSCs 
are stem cells that have the capacity for self-reneWal through 
out the life span of an organism. HoWever, ST-HSCs exhibit 
transient self-reneWal properties for a limited period of time 
(e. g., typically less than 8 Weeks in a mouse) prior to under 
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going full differentiation. HSCs can differentiate into 
hematopoietic progenitor cells (“HPCs”) that can further dif 
ferentiate into clonogenic cells, or cells of a single lineage. 
For example, the differentiation of common lymphoid pro 
genitors (“CLPs”) can produce T lymphocytes (“T cells”), B 
lymphocytes (“B cells”), and natural killer cells (“NKs”). The 
differentiation of common myeloid progenitors (“CMPs”) 
can generate blood cells of other lineages, including erythro 
cytes, macrophages, granulocytes, and platelets. The mainte 
nance of mature blood-bome cells in the peripheral circula 
tion is critical for various processes, including oxygen 
delivery and immunological protection. 
Bone marroW transplantation (“BMT”) and hematopoietic 
stem cell transplantation (“HSCT”) can be effective for the 
treatment of diseases of the blood, diseases of the bone mar 
roW, cancers of the blood, and cancers of the bone marroW, 
including various types of anemia, leukemia, and immuno 
logical disorders. For example, obtaining HSCs by bone mar 
roW harvesting from donors can be technically challenging in 
that harvesting suf?cient material from the bone marroWs of 
donors involves multiple insertions of large needles to obtain 
suf?cient amount of stem cells. Methods for regenerating 
HSCs can be useful for treating patients affected by various 
types of disorders, diseases, or cancers that deleteriously 
affect the number of endogenous HSCs Within a patient. 
SUMMARY OF THE INVENTION 
An ex vivo method for producing a reneWed population of 
hematopoietic stem cells (HSCs) is provided, in Which a ?rst 
HSC population from a donor is obtained, the ?rst HSC 
population is contacted With an antagonist that reduces 
latexin expression and/ or latexin activity, and the HSC popu 
lation is cultured under in vitro conditions that can promote 
cell proliferation and/or inhibit apoptosis to obtain a second 
HSC population that comprises a progeny of the ?rst HSC 
population. 
A method for reconstituting a recipient host With a HSC 
population generated ex vivo is provided, in Which a ?rst HSC 
population from a donor is obtained, the ?rst HSC population 
is contacted With an antagonist that reduces latexin expres 
sion and/or latexin activity, the HSC population is cultured 
under in vitro conditions that can promote cell proliferation 
and/or inhibit apoptosis to obtain a second HSC population 
that comprises a progeny of the ?rst HSC population, and the 
second HSC population is transplanted to the recipient ho st in 
need of HSC reconstitution. 
A method for reconstituting a recipient host With a HSC 
population generated in vivo is provided, in Which the recipi 
ent host is administered With a pharmaceutical composition 
comprising an antagonist that reduces latexin expression and/ 
or latexin activity. 
BRIEF DESCRIPTION OF DRAWINGS 
FIG. 1 illustrates various biochemical pathWays mediated 
by latexin that may be involved in the regulation of HSC 
proliferation in mammals, as described in Example 1. 
FIG. 2 illustrates a genomic map of congenic intervals 
identi?ed in reciprocal Chr.3 congenic mouse strains, as 
described in Example 1. 
FIG. 3 illustrates a genome-Wide linkage analysis based on 
GeneNetWork that associates the trait regulating HSC popu 
lation siZe With three quantitative trait loci (QTL) on Chro 
mosomes (Chr) 3, 5, and 18, respectively, as described in 
Example 4. 
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FIG. 4A illustrates the CAFC day 35 frequency observed 
for femur cells of Chr3 congenic mice compared to back 
ground mice, as described in Example 5. 
FIG. 4B illustrates the CAFC day 35 frequency observed 
for LSK cells of Chr3 congenic mice compared to back 
ground mice, as described in Example 5. 
FIG. 4C illustrates the effect of D2 alleles on the number of 
long-term repopulating HSCs in BD Chr3 mice, as described 
in Example 5. 
FIG. 5A illustrates that D2 alleles confer an increase in 
HSC replication and that B6 alleles confer a decrease in HSC 
replication, as described in Example 6. 
FIG. 5B illustrates the effect of Chr 3 QTL on the cell-cycle 
kinetics of hematopoietic progenitor cells (HPCs), as 
described in Example 6. 
FIG. 5C illustrates that D2 alleles of the Chr 3 QTL confer 
HSCs With higher self-reneWal capability, as described in 
Example 7. 
FIG. 5D illustrates bone marroW LSK cells subject to apo 
ptosis as detected by Annexin V-staining, as described in 
Example 8. 
FIG. 5E illustrates the effect of Chr 3QTL on apoptosis of 
LSK cells in steady-state B6 D2 and Chr3 congenic bone 
marroWs, as described in Example 8. 
FIG. 6A illustrates Lxn mRNA expression in congenic 
LSK cells compared With B6 and D2 cells, as described in 
Example 10. 
FIG. 6B illustrates quantitation of Lxn transcripts by real 
time PCR in peripheral blood leukocytes, Whole bone mar 
roW, Lin-negative bone marroW cells, and LSK stem cells, as 
described in Example 11. 
FIG. 6C illustrates immunoreactivity betWeen the anti 
mouse LXN antibody and a protein (29 kD) from bone mar 
roW cells by a Western Blot, as described in Example 12. 
FIG. 6D illustrates the levels of LXN protein in Whole bone 
marroW and Lin-negative cells, as described in Example 12. 
FIG. 7A illustrates various QTLs that may be involved in 
the regulation of Lxn expression, as described in Example 13. 
FIG. 7B illustrates a CpG island analysis in the upstream 
sequence of Lxn open-reading frame, as described in 
Example 13. 
FIG. 8A illustrates a schematic for in vitro infection of 
bone marroW cells With retroviral vectors containing either 
GFP or Lxn (Lxn-GFP), and subsequent transplantation into 
irradiated mouse recipients, as described in Example 14. 
FIG. 8B illustrates results of a Western blot analysis of 
GFP+ cells sorted from the BM of the recipient mice trans 
planted With either Lxn-GFP or GFP-transduced cells, as 
described in Example 14. 
FIG. 8C illustrates results of CAFC day 35 frequency assay 
of D2 bone marroW cells transduced With either GFP control 
or Lxn-GFP, as described in Example 14. 
FIG. 8D illustrates results of long-term repopulating cells 
(LTRC) frequency assay of BD Chr.3 congenic BM cells 
transduced With either GFP control or Lxn-GFP, as described 
in Example 14. 
FIG. 9A illustrates exemplary SiRNAs transfected into 
NIH3T3 cells, as described in Example 15. 
FIG. 9B illustrates the results of sequence-speci?c SiRNA 
mediated inhibition of latexin mRNA expression in mouse 
adult stem cells that resulted in HSC proliferation and HSC 
apoptotic inhibition, as described in Example 15. 
DETAILED DESCRIPTION OF THE INVENTION 
Various embodiments provide methods and related com 
positions useful for reconstituting hematopoietic stem cells 
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(HSCs) Within a patient in need of HSC reneWal. For 
example, the present methods are useful for the treatment of 
patients affected With disorders, diseases, and/ or cancers that 
deleteriously compromise the number of endogenous HSCs 
and differentiated forms of such HSCs Within patients. 
Examples of disorders, diseases, and/or cancers contem 
plated for treatment by the present methods and compositions 
include diseases of the blood, diseases of the bone marroW, 
cancers of the blood, and cancers of the bone marroW, includ 
ing various types of anemia, leukemia, immunological disor 
ders, thalassemia major, sickle-cell disease, myelodysplastic 
syndrome, lymphoma, aplastic anemia, and multiple 
myeloma. Patients that may bene?t from treatments that uti 
liZe the present methods and related compositions include 
candidates for bone marroW transplantation (“BMT”) and 
hematopoietic stem cell transplantation (“HSCT”). Trans 
plantation therapies can be effective for the treatment of vari 
ous types of leukemia and any disorder/disease/cancer for 
Which patients are subjected to radiotherapy and/ or chemo 
therapy. The reneWed or regenerated population of HSCs that 
can be induced by the present methods and compositions are 
useful for various applications, including regenerative medi 
cine, tissue engineering, tissue repair, cancer therapy, and 
gene therapy. As described in the folloWing embodiments, a 
given HSC population obtained from a donor or Within a 
recipient host (i.e., a patient) can be induced to proliferate 
and/or to suppress apoptosis by providing antagonistic com 
pounds/compositions that can inhibit latexin expression and/ 
or latexin activity. 
I. De?nitions 
As used throughout the speci?cation and the appended 
claims, the terms listed beloW have the folloWing meanings, 
Wherein “a” means one or more: 
The terms “hematopoietic stem cells” (“HSCs”) refer to a 
heterogeneous mixture of undifferentiated progenitor stem 
cells, mainly composed of long-term HSCs (“LT-HSCs”) and 
short-term HSCs (“ST-HSCs”). LT-HSCs are undifferenti 
ated stem cells that have the capacity for self-reneWal 
throughout the life span of an organism. ST-HSCs are undif 
ferentiated stem cells that have the capacity for self-reneWal 
for a limited time prior to full differentiation into a speci?c 
lineage. For example, HSCs can differentiate into hematopoi 
etic progenitor cells (“HPCs”) that can further differentiate 
into clonogenic cells, or cells of a single lineage, that repre 
sent a subset of a hematopoietic lineage. HSCs include non 
embryonic stem cells isolated from post-natal animals. HSCs 
include “pluripotent adult stem cells” isolated from the bone 
marroWs of mammals that are capable of differentiating into 
tissues of all three germ or dermal layers, such as the meso 
derm, endoderm, and ectoderm. A “pluripotent stem cell” 
refers to a stem cell that exhibits the capacity to groW into any 
type of cell that constitutes an organism. A pluripotent cell 
can be self-reneWing and can remain dormant/quiescent 
Within a tissue. HSCs include “multipotent stem cells” that 
exhibit the capacity to groW into any subset of cells that 
constitute an organism. HSCs include undifferentiated stem 
cells that exhibit a distinct pro?le of cell surface markers, 
including the folloWing combination of markers: Thy-1Z0 Sca 
1+ Lineage- c-kit"; or CD 150+ CD48- Sca-l+ Lineage 
c-kit"; or Thy-1Z0 CD150+ CD48“ Sca-l+ Lineage“ c-kit+ 
(Kiel et al., Cell, Vol. 121, p 1109-1121 (2005)). HSCs that 
express the combination of human counterparts for these 
markers are preferably contemplated. The folloWing refer 
ences are herein incorporated by reference in their entirety: 
Cheshier et al., P.N.A.S., Vol. 96, p 3120-3125 (1999); Eck 
US 8,110,184 B2 
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feldt et al., Nature, Vol. 6, p 726-737 (2005); Wright et. al., 
Science, Vol. 94, p 1933-1936 (2001); and Preston et al., J. 
Clin. Pathol. Vol. 56, p 86-96 (2003). 
The term “?rst HSC population” refers to HSCs obtained 
from a donor, Wherein the ?rst HSC population expresses cell 
surface markers as described supra. 
The term “second HSC population” refers to the progeny of 
the ?rst HSC population produced by in vitro cell prolifera 
tion under in vitro conditions, Wherein the second HSC popu 
lation expresses cell surface markers as described supra. 
The term “latexin” (“Lxn”) refers to the Lxn gene, iso 
forms/variants of the Lxn gene, and gene products derived 
from the Lxn gene, including messenger RNA and protein. 
The sense-strand of a human latexin cDNA is provided as 
SEQ ID NO: 1. A human latexin protein sequence is provided 
as SEQ ID NO:2. Latexin isoforms/variants include genes 
containing exon sequences having at least about 70%, 75%, 
80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence 
similarity to SEQ ID NO: 1; genes containing exon sequences 
having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 
97%, 98%, or 99% sequence identity to SEQ ID NO: 1; those 
sequences encoded by genes containing exon sequences hav 
ing at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 
97%, 98%, or 99% sequence similarity to SEQ ID NO:1; 
those sequences encoded by genes containing exon 
sequences having at least about 70%, 75%, 80%, 85%, 90%, 
95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID 
NO: 1; those sequences having at least about 70%, 75%, 80%, 
85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence similar 
ity to SEQ ID NO:2; and those sequences having at least 
about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 
99% sequence identity to SEQ ID NO:2. Latexin isoforms/ 
variants include mammalian homologs listed in Tables 1-3. 
Examples of latexin isoforms/variants include the carbox 
ypeptidase inhibitor (CARIN) described in US. Pat. No. 
5,998,373. 
The term “antagonist” refers to any compound or compo 
sition that can inhibit the expression and/or the activity of 
latexin and latexin isoforms, including sequence-speci?c 
polynucleotides that can interfere With the transcription of 
endogenous latexin gene; sequence-speci?c polynucleotides 
that can interfere With the translation of latexin mRNA tran 
scripts (e.g., siRNAs, ribozymes); sequence-speci?c 
polypeptides that can interfere With the protein stability of 
latexin, the enzymatic activity of latexin, and/or the binding 
activity of latexin With respect to substrates and/or regulatory 
proteins; and small molecule compounds that can interfere 
With the protein stability of latexin, the enzymatic activity of 
latexin, and/or the binding activity of latexin. An effective 
antagonist can promote HSC proliferation by at least 25%, 
30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 
80%, 85%, 90%, 95%, or 100%. An effective antagonist can 
suppress HSC apoptosis by at least 25%, 30%, 35%, 40%, 
45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 
95%, or 100%. 
11. Regulation of Cell Cycling, Apoptosis and 
Proliferation of Hematopoietic Stem Cells (HSCs) 
Mediated by Latexin 
The present inventors have identi?ed a quantitative trait 
loci (“QTL”) that confers variation in HSC numbers in young 
and adult C57BL/ 6 (B6) and DBA/2 (D2) mice. By utilizing 
reciprocal Chromosome 3 congenic mice derived from these 
tWo parental strains, such as B.D Chr3 and DB Chr3 mice, 
the present inventors have demonstrated that intro gressed D2 
alleles confer an increase in HSC population size by enhanc 
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ing HSC cell proliferation (i.e., HSC self-reneWal) and/or by 
suppressing HSC apoptosis, as seen in BD Chr3 congenic 
mice. In contrast, the B6 alleles conferred a decrease in HSC 
population size. Differential expression levels conferred by 
these alleles correlated With the latexin (“Lxn”) gene locus. 
Differential latexin expression levels Were shoWn to inversely 
correlate With HSC population size, based on experimental 
data obtained utilizing oligonucleotide arrays (e. g., microar 
rays), real-time PCR, and Western blots. Ectopic expression 
of latexin protein from a retroviral construct resulted in a 
decrease in stem cell population size. Clusters of single nucle 
otide polymorphisms (SNPs) Were identi?ed upstream of the 
Lxn transcriptional start site. At least tWo of these clusters 
appear to be associated With potential binding sites for tran 
scription factors involved in hematopoietic stem cell regula 
tion. Thus, promoter polymorphisms betWeen B6 and D2 
alleles appear to affect Lxn gene expression, and conse 
quently, to in?uence HSC population size. The results of 
these experiments are presented in FIGS. 1-9 and are further 
described in Examples 1-15. 
Latexin Was identi?ed initially as an antigen expressed 
Within the rat cerebral cortex. Latexin mRNA and protein (29 
kDa) have been shoWn by others to be expressed in neural and 
non-neural tissues. Latexin exhibits inhibitory activity 
against rat carboxypeptidaseAl (“CPA1”), carboxypeptidase 
A2 (“CPA2), and mast-cell CPA (Uratani et al., Biochem. 1., 
Vol 346: 817-826 (2000). CPA and CPB are pancreatic zinc 
containing proteolytic enzymes that catalyze the hydrolysis 
of the carboxyl-terminal peptide bond Within polypeptide 
chains. Carboxypeptidase activities canbe regulated either by 
endogenous protein inhibitors or by enzymatic cleavage of a 
segment of a propeptide that releases the active form of the 
carboxypeptidase. Both latexin and Tissue Carboxypeptidase 
Inhibitor (TCl) are examples of endogenous protein inhibi 
tors of carboxypeptidases. Latexin and TCI contain several 
potential phosphorylation sites, and both are expressed and 
localized in the cytosol of a number of tissues, including the 
brain, the lung, and the digestive tract. 
FIG. 1 illustrates various biochemical pathWays mediated 
by latexin that may be involved in the regulation of HSC 
proliferation in mammals. Lxn is the only knoWn endogenous 
carboxypeptidase A (CPA) inhibitor in mammals. Structural 
similarity betWeen latexin and cystatins that inhibit cathep 
sins in the lysosomal protein degradation pathWay suggests 
an in?ammatory role of latexin in activated macrophages. 
Thus, latexin may be involved in the metabolism of speci?c 
proteins that are essential for HSC functions. Lxn appears to 
exhibit tWo potential Ca2+/calmodulin-dependent protein 
kinase sites and one c-GMP-dependent protein kinase phos 
phorylation site. Thus, the c-GMP/PKG and/or calcium/ 
calmodulin signaling pathWays may be involved in the Lxn 
mediated regulation of HSCs. The physical structure of 
latexin includes tWo nearly identical domains that have high 
conformational homology With the cystatins that can inhibit 
cathepsins in the lysosomal protein degradation pathWay. 
Thus, Lxn appears to have an in?ammatory role in activated 
macrophages, and to be involved in the metabolism of spe 
ci?c proteins that are essential for HSC functions. The 
c-GMP/ PKG and/ or calcium/calmodulin signaling pathWays 
may be involved in Lxn-mediated regulation of HSCs based 
on the fact that Lxn contains tWo potential Ca2+/calmodulin 
dependent protein kinase sites and one c-GMP-dependent 
protein kinase phosphorylation site. These possible pathWays 
may act synergistically or independently in the regulation of 
HSC cycling, apoptosis, and/or proliferation that affect HSC 
population size. 















